How to buy Vaccinex stock

Vaccinex, Inc is a biotechnology business based in the US. Vaccinex shares (VCNX) are listed on the NASDAQ and all prices are listed in US Dollars. Vaccinex employs 39 staff and has a trailing 12-month revenue of around 0.00.

Vaccinex share price

Use our graph to track the performance of VCNX stocks over time.

Vaccinex shares at a glance

• Key figures

Information last updated 2021-04-23.

52-week range	$1.63 - $9.40
50-day moving average	$2.96
200-day moving average	$2.54
Wall St. target price	$7.00
PE ratio	N/A
Dividend yield	N/A (0%)
Earnings per share (TTM)	$-3.01

Buy Vaccinex shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

*Signup bonus information updated weekly.

Is it a good time to buy Vaccinex stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Technical Analysis of Vaccinex, Inc by TradingView

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Vaccinex financials

Revenue TTM	$625,000
Gross profit TTM	$-20,926,000
Return on assets TTM	-217.18%
Return on equity TTM	-748.42%
Profit margin	0%
Book value	$-2.30
Market capitalisation	$71.1 million

TTM: trailing 12 months

Shorting Vaccinex shares

There are currently 477,891 Vaccinex shares held short by investors – that's known as Vaccinex's "short interest". This figure is 0.9% up from 473,477 last month.

There are a few different ways that this level of interest in shorting Vaccinex shares can be evaluated.

Vaccinex's "short interest ratio" (SIR)

Vaccinex's "short interest ratio" (SIR) is the quantity of Vaccinex shares currently shorted divided by the average quantity of Vaccinex shares traded daily (recently around 937041.17647059). Vaccinex's SIR currently stands at 0.51. In other words for every 100,000 Vaccinex shares traded daily on the market, roughly 510 shares are currently held short.

However Vaccinex's short interest can also be evaluated against the total number of Vaccinex shares, or, against the total number of tradable Vaccinex shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Vaccinex's short interest could be expressed as 0.02% of the outstanding shares (for every 100,000 Vaccinex shares in existence, roughly 20 shares are currently held short) or 0.0284% of the tradable shares (for every 100,000 tradable Vaccinex shares, roughly 28 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Vaccinex.

Find out more about how you can short Vaccinex stock.

Vaccinex share dividends

We're not expecting Vaccinex to pay a dividend over the next 12 months.

Vaccinex share price volatility

Over the last 12 months, Vaccinex's shares have ranged in value from as little as $1.63 up to $9.4. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Vaccinex's is 1.8181. This would suggest that Vaccinex's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Vaccinex overview

Vaccinex, Inc. , a clinical-stage biotechnology company, engages in the discovery and development of targeted biotherapeutics to treat serious diseases and conditions with unmet medical needs. The company offers its products for the treatment of cancer, neurodegenerative diseases, and autoimmune disorders. Its lead product candidate is pepinemab, a humanized monoclonal antibody that is in Phase 1 and 2 clinical trials for the treatment of non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC), Huntington's disease, Alzheimer's disease, osteosarcoma, and melanoma. The company is also developing VX5, a human antibody to CXCL13 that is in preclinical development for the treatment of MS and for other autoimmune disorders; and VX25, a bi-specific molecule based on natural killer T (NKT) vaccine platform for the therapeutic application of NKT cell stimulation for cancer immunotherapy. Vaccinex, Inc. was incorporated in 2001 and is headquartered in Rochester, New York.

Frequently asked questions

• What percentage of Vaccinex is owned by insiders or institutions?

  Currently 14.452% of Vaccinex shares are held by insiders and 34.996% by institutions.

• How many people work for Vaccinex?

  Latest data suggests 39 work at Vaccinex.

• When does the fiscal year end for Vaccinex?

  Vaccinex's fiscal year ends in December.

• Where is Vaccinex based?

  Vaccinex's address is: 1895 Mount Hope Avenue, Rochester, NY, United States, 14620

• What is Vaccinex's ISIN number?

  Vaccinex's international securities identification number is: US9186401033

• What is Vaccinex's CUSIP number?

  Vaccinex's Committee on Uniform Securities Identification Procedures number is: 918640103